• Homepage
• Information
  • About Read-Gene
  • News
  • Offer
  • Company Structure
  • Intellectual Property
  • Our Team
  • Advisory Board
  • Media about us
• For Investors
  • Company
    • Management Board
    • Shareholders
    • General Meetings
    • Corporate Act
    • Contact
    • FAQ
  • Financial Information
    • Financial data
    • Basic Financial Figures
  • Reports
    • Current
    • Periodical
  • NEWCONNECT
    • Basic Information
    • History of Transactions
    • Information Document
  • Calendar
    • Event calendar
  • Presentations
    • Presentations for investors
    • Press Release
• DNA tests
• Consultation
• Contact

Read-Gene - Innovative Genetics

READ-GENE SA is a company of innovative technologies, which aim is to commercialize methods of detection, prevention and treatment of the most common types of malignant tumours.

The success of READ-GENE SA in the recruitment of patients with ovarian cancer and BRCA1 mutation in a trial a new drug treatment, 2009-02-22

AstraZeneca in cooperation with monitoring firm Parexel has completed recruitment for testing new drug called "inhibilator PARP" designated for the treatment of diseases of the ovary at patients with mutation BRCA1. READ-GENE  adopted to study the largest number of patients amongst several centers around the world for participation in research invited.

More information: Information - Media about us - Recuitment.pdf